JACOBIO-B(01167): The new drug JAB-23E73, a Pan-KRAS inhibitor, has been approved for clinical trial application (IND) by the US FDA.

JACOBIO-B(01167) announced that the company's independently developed Pan-KRAS inhibitor JAB-23E73 has received approval from the US Food and Drug Administration (FDA) for an Investigational New Drug (IND) application, and will conduct Phase I/IIa late-stage solid tumor clinical trials in the United States. The IND application in China has been submitted to the China National Medical Products Administration Drug Evaluation Center and clinical trials will be conducted in China upon approval. KRAS mutations are widely present in various types of tumors, with approximately 23%-25% of cancer patients having KRAS mutations. Globally, an estimated 2.7 million new tumor patients with KRAS-related mutations are expected to benefit from Pan-KRAS inhibitors. JAB-23E73 can simultaneously inhibit the active and inactive states of KRAS, without significant inhibition of HRAS or NRAS. As an oral KRAS inhibitor, preclinical data of JAB-23E73 demonstrates favorable pharmacokinetic properties.